This is to inform that, pursuant to Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation of our intimation dated 04th September, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanza Biosciences has filed a revised Annual Report for FY 2024-25 with BSE, replacing the version originally submitted on September 4, 2025 due to improper formatting and changes. The revised report contains the full AGM notice for the 43rd Annual General Meeting scheduled for September 25, 2025 at 3:00 p.m. via video conferencing. Key business items in the report include adoption of audited standalone and consolidated financial statements, appointment of a new Secretarial Auditor for five years (FY 2025-26 to 2029-30), regularization of two new directors, and a notable proposal to alter the company's object clause to enter businesses like agro products, solar and renewable energy, drones, IT and software services, data centers, real estate, and EPC projects. Several board changes occurred during the year, including resignations of two directors and the previous Company Secretary, and new appointments of an Independent Director, a Non-Independent Director, and a new Company Secretary.
This is a routine administrative correction rather than new news, but the revised report surfaces a significant strategic shift — shareholders are being asked to approve a wide diversification of the company's business objects far beyond its core biosciences identity. Investors should review the detailed financials, the MOA alteration resolution (Special Business Item 6), and the director changes before the September 25, 2025 AGM.